Canton Strategic Holdings (CNTN) Change in Accured Expenses (2021 - 2026)
Canton Strategic Holdings (CNTN) posted Change in Accured Expenses of -$1.5 million for Q1 2026, down 196.73% on a QoQ basis from $1.5 million in Q4 2025, and down 22752.21% year-over-year from N/an in Q1 2025.
Canton Strategic Holdings (CNTN) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Canton Strategic Holdings' Change in Accured Expenses history runs 6 years deep, the most recent figure standing at -$1.5 million for Q1 2026.
- Quarterly Change in Accured Expenses fell 22752.21% year-over-year to -$1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$378695.0 (down 147.91% YoY) and the FY2025 annual result came in at $1.1 million, up 156.55% from the prior year.
- Change in Accured Expenses was -$1.5 million for Q1 2026 at Canton Strategic Holdings, down from $1.5 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.5 million in Q4 2025 and bottomed at -$1.5 million in Q1 2026.
- A 5-year average of $36530.7 and a median of -$6376.0 in 2025 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 6658.29% — and 2026, when it slumped 22752.21%.
- Canton Strategic Holdings' Change in Accured Expenses stood at $10597.0 in 2022, then surged by 6658.29% to $716176.0 in 2023, then slumped by 106.25% to -$44774.0 in 2024, then jumped by 3464.2% to $1.5 million in 2025, then slumped by 196.73% to -$1.5 million in 2026.
- Business Quant data shows CNTN's Change in Accured Expenses at -$1.5 million in Q1 2026, $1.5 million in Q4 2025, and -$368137.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -16.82 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -16.74 Mn |
| 10 | Canton Strategic Holdings | 427.87 Mn | 427.87 Mn | - | -1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.46 Mn |
| Mar 31, 2026 | -1.46 Mn |
| Dec 31, 2025 | 1.51 Mn |
| Dec 31, 2025 | 1.51 Mn |
| Sep 30, 2025 | -368,137.00 |
| Sep 30, 2025 | -368,137.00 |
| Jun 30, 2025 | -59,787.00 |
| Jun 30, 2025 | -59,787.00 |
| Mar 31, 2025 | -6,376.00 |
| Mar 31, 2025 | -6,376.00 |
| Dec 31, 2024 | -44,774.00 |
| Dec 31, 2024 | -44,774.00 |
| Sep 30, 2024 | 789,628.00 |
| Sep 30, 2024 | 789,628.00 |
| Jun 30, 2024 | 51,935.00 |
| Jun 30, 2024 | 51,935.00 |
| Mar 31, 2024 | -378,942.00 |
| Mar 31, 2024 | -378,942.00 |
| Dec 31, 2023 | 716,176.00 |
| Dec 31, 2023 | 716,176.00 |